Nov. 27, 2012 – An Oct. 31 enforcement letter from the FDA’s Office of Prescription Drug Promotion (OPDP) to Cornerstone Therapeutics Inc. for CUROSURF Intratracheal Suspension sent a strong message to medical public relations professionals because it was one of two enforcement letters issued within a two-week period that cited press materials, not the advertising […]
Read more